Goldman Keeps Neutral on Gilead After Strong Q4; Stock Near Yearly High
Goldman Sachs reiterated a Neutral rating and a $125 price target on Gilead Sciences after the company's fourth-quarter results. Gilead reported non-GAAP EPS of $1.86 and revenue of $7.93 billion, driven by HIV and oncology sales, and issued initial fiscal 2026 guidance calling for HIV growth and a decline in cell therapy.